<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115256</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-0636</org_study_id>
    <nct_id>NCT02115256</nct_id>
  </id_info>
  <brief_title>Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline</brief_title>
  <official_title>Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaakov Beilin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breech presentation of a term pregnancy is a common occurrence. A procedure known as external
      cephalic version (ECV) is frequently used by obstetricians to turn the baby into the vertex
      position prior to delivery in order to avoid a cesarean section and the associated risks.
      Medications to relax the uterus, known as tocolytics, are used in conjunction with the
      procedure as they have been shown to improve the success rate of ECV, but with inconsistent,
      varying results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breech presentation occurs in approximately 3-4% of all births and all women with breech
      presentation at term undergo cesarean delivery. The only way to avoid a cesarean is to
      manually turn the baby prior to the date of delivery, a procedure known as elective external
      cephalic version (ECV). ECV has been shown to reduce the frequency of breech presentation at
      term and thus lessen the risks associated with breech delivery and those of cesarean section,
      with little risk to the mother or baby. Tocolysis, administered immediately prior to the ECV
      and commonly used at The Mount Sinai Hospital, has been shown to improve the success rate of
      ECV. Several different agents are known to cause tocolysis. These include beta-mimetics
      (ritodrine, terbutaline), nitroglycerine (NTGL) and nifedipine.Terbutaline has been shown to
      improve success rate of ECV. Another study published in 2004 by El-Sayed et al showed that
      subcutaneous terbutaline was associated with higher rates of successful ECV than IV NTGL in
      term patients. There is inconsistent data in regard to the success rate of ECV with NTGL. In
      a study published in 2003 by Bujold et al, NTGL was associated with a higher rate of side
      effects and a lower rate of successful ECV when compared to ritodrine. Another study
      published in 2009 by Hilton et al showed that NTGL was more efficacious for ECV in
      nulliparous versus multiparous women. Yet another study published in 2009 by Yanny et al
      showed no differences between sublingual NTGL versus placebo in efficacy, and reported no
      significant side effects. A study published in 2003 by Bujold et al showed that sublingual
      NTGL was associated with a higher incidence of headache and did not improve the success rate
      of ECV. It may be beneficial to use NTGL instead of terbutaline because NTGL is a shorter
      acting agent and the procedure itself only lasts 10-15 minutes. Additionally, both
      medications have side effects. Terbutaline is associated with maternal tachycardia,
      hyperglycemia, hypokalemia, pulmonary edema, cardiac arrhythmias, hypertension and myocardial
      ischemia, and NTGL is associated with maternal nausea, vomiting, headache, and hypotension.
      For both medications the side effects are self- limiting but depending on the patient's
      co-morbidities one drug may be beneficial for that individual patient.

      To date no study has compared the efficacy of intravenous terbutaline versus intravenous NTGL
      in women presenting for ECV. The purpose of this study is to determine if the success rate of
      ECV can be improved with the use of IV NTGL.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult recruitment
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Version of the Fetus Into the Vertex Position</measure>
    <time_frame>average of 1 hour</time_frame>
    <description>Number of participants that had successful version of the fetus into the vertex position.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypotension</measure>
    <time_frame>average of 1 hour</time_frame>
    <description>Number of participants with hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Cesarean Delivery</measure>
    <time_frame>average of 1 hour</time_frame>
    <description>Number of participants that needed a cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tachycardia</measure>
    <time_frame>average of 1 hour</time_frame>
    <description>Number of participants that had tachycardia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>External Cephalic Version</condition>
  <arm_group>
    <arm_group_label>Intravenous Terbutaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25 mL of Intravenous Terbutaline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Nitroglycerine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Terbutaline</intervention_name>
    <description>0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
    <arm_group_label>Intravenous Terbutaline</arm_group_label>
    <other_name>Terbutaline</other_name>
    <other_name>Brethine</other_name>
    <other_name>Bricanyl</other_name>
    <other_name>Brethaire</other_name>
    <other_name>Terbutalin</other_name>
    <other_name>(RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Nitroglycerine</intervention_name>
    <description>The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
    <arm_group_label>Intravenous Nitroglycerine</arm_group_label>
    <other_name>Nitroglycerine</other_name>
    <other_name>Nitroglycerin</other_name>
    <other_name>Trinitroglycerin</other_name>
    <other_name>Trinitroglycerine</other_name>
    <other_name>nitro</other_name>
    <other_name>1,2,3-trinitroxypropane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Between 18-35 years of age

          -  37 weeks gestation

          -  Breech presentation

        Exclusion Criteria:

          -  Patients with ruptured membranes

          -  Multiple gestation

          -  Maternal age (age &gt; 35)

          -  With known medical comorbidities (including hypertension (HTN), arrhythmias,
             endocrinologic diseases such as diabetes and thyroid disease, scoliosis, asthma)

          -  Allergies to nitroglycerine or terbutaline

          -  Prior abdominal or uterine surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaakov Beilin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2014</study_first_submitted>
  <study_first_submitted_qc>April 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>May 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 14, 2017</last_update_submitted>
  <last_update_submitted_qc>May 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Yaakov Beilin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>External Cephalic Version</keyword>
  <keyword>breech</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>6 Participants were enrolled from 06/12/2014 to 05/12/2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Terbutaline</title>
          <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Nitroglycerine</title>
          <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Terbutaline</title>
          <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Nitroglycerine</title>
          <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="1"/>
                    <measurement group_id="B2" value="36" spread="2"/>
                    <measurement group_id="B3" value="34" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Version of the Fetus Into the Vertex Position</title>
        <description>Number of participants that had successful version of the fetus into the vertex position.</description>
        <time_frame>average of 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Terbutaline</title>
            <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Nitroglycerine</title>
            <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Version of the Fetus Into the Vertex Position</title>
          <description>Number of participants that had successful version of the fetus into the vertex position.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypotension</title>
        <description>Number of participants with hypotension</description>
        <time_frame>average of 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Terbutaline</title>
            <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Nitroglycerine</title>
            <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypotension</title>
          <description>Number of participants with hypotension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Cesarean Delivery</title>
        <description>Number of participants that needed a cesarean delivery</description>
        <time_frame>average of 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Terbutaline</title>
            <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Nitroglycerine</title>
            <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Cesarean Delivery</title>
          <description>Number of participants that needed a cesarean delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tachycardia</title>
        <description>Number of participants that had tachycardia</description>
        <time_frame>average of 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Terbutaline</title>
            <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Nitroglycerine</title>
            <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
          </group>
        </group_list>
        <measure>
          <title>Tachycardia</title>
          <description>Number of participants that had tachycardia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Terbutaline</title>
          <description>0.25 mL of Intravenous Terbutaline
Intravenous Terbutaline: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Nitroglycerine</title>
          <description>IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Intravenous Nitroglycerine: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it’s short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yaakov Beilin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-7467</phone>
      <email>yaakov.beilin@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

